Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 173

Sort by

Sort Order Select

Journal Articles

Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma

Jennifer E. Amengual, Aung M. Tun, Ted B. Piorczynski, Yun Kyoung Tiger, Victor Yazbeck, Hua-Jay J Cherng, Seda S. Tolu, Barbara Pro, Diane Durecki, Jan Beumer, Neil Kelleher, Naomi Sender, Sarah Sta Ana, Anxhela Kalia, Beatriz Raposo Corradini, Yu Shyr, Patricia LoRusso, Lorraine Pelosof, Richard Piekarz

Blood (2024) 144 (Supplement 1): 3112.

https://doi.org/10.1182/blood-2024-199650

Published: 2024

Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial

Neha Mehta-Shah, Pier Luigi Zinzani, Eric D. Jacobsen, Jasmine Zain, Monica Mead, Carla Casulo, Giuseppe Gritti, Lauren C. Pinter-Brown, Koji Izutsu, Ohad S Bentur, David Sidransky, Jonathan E. Brammer, Barbara Pro, Christopher P. Fox, Steven Horwitz

Blood (2024) 144 (Supplement 1): 3061.

https://doi.org/10.1182/blood-2024-203577

Published: 2024

Journal Articles

Association between Food Insecurity, Financial Toxicity, and Healthcare Utilization in Patients with Lymphoma

Kishan A Bhatt, David M. DeStephano, Rhea K Khurana, Claire Sathe, Seda S. Tolu, Hua-Jay J. Cherng, Jennifer E. Amengual, Barbara Pro, Dawn L Hershman, Justine M. Kahn, Melissa P Beauchemin

Blood (2024) 144 (Supplement 1): 5042.

https://doi.org/10.1182/blood-2024-210508

Published: 2024

Journal Articles

Health Disparities in Lived Experiences of Patients with Cutaneous T-Cell Lymphoma: An All of Us Database Analysis

Sara Suhl, Alexander Kaminsky, Abigail Marx, Sophia Luyten, Ikenna David Nebo, Barbara Pro, Larisa J Geskin

Blood (2024) 144 (Supplement 1): 2340.

https://doi.org/10.1182/blood-2024-212039

Published: 2024

Journal Articles

Combination JAK Inhibition and Immune Checkpoint Blockade for the Treatment of 9p Amplified Lymphomas

Seda S. Tolu, Ted B. Piorczynski, Manuel Pazos, II, Brian Estrella, Hua-Jay J Cherng, Barbara Pro, Jennifer E. Amengual

Blood (2024) 144 (Supplement 1): 336.

https://doi.org/10.1182/blood-2024-203382

Published: 2024

Journal Articles

Extended Follow up and Immune Alterations in Patients with Classic Hodgkin Lymphoma (cHL) Treated with Frontline Single Agent Pembrolizumab Followed By AVD Chemotherapy

Pamela B. Allen, Latifa Bazzi, Bin Zhang, Qing Chen, Liron Barnea Slonim, Hatice Savas, Ranjana H. Advani, Andrew M Evens, Barbara Pro, Reem Karmali, Eric Mou, Robert Eisner, Robert Bayer, Leo I. Gordon, Jane N. Winter

Blood (2024) 144 (Supplement 1): 1664.

https://doi.org/10.1182/blood-2024-208680

Published: 2024

Journal Articles

Diagnostic Utility of the 18 f-FDG PET/CT Scan in Solid Organ Transplant Patients with EBV Reactivation at Risk for Post-Transplant Lymphoproliferative Disorder

Hua-Jay J Cherng, Rebecca Scalabrino, Patrick Gould, Alexander Sanjurjo, Brian Cuzzo, Saagar Jain, Hong Y Ma, Maegan Ford, Evelyn H. Orlando, Dorine De Jong, Manuela A Orjuela, Andrew H. Lipsky, Seda S. Tolu, Barbara Pro, Jennifer E. Amengual, Kathleen M Capaccione

Blood (2024) 144 (Supplement 1): 3077.

https://doi.org/10.1182/blood-2024-194265

Published: 2024

Journal Articles

The Effect of Preemptive Rituximab Treatment in Patients with EBV Viremia after Solid Organ Transplantation on the Development of Post-Transplant Lymphoproliferative Disorder

Blood (2023) 142 (Supplement 1): 990.

https://doi.org/10.1182/blood-2023-177823

Published: 2023

Journal Articles

Outcomes of Contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL

Seda S. Tolu, Caitlin Gribbin, Madhav R Seshadri, Zhengming Chen, Evelyn Orlando, Justin Grenet, Rajbir Toor, Alexander Sanjurjo, Adrienne A. Phillips, Tsiporah B. Shore, Peter Martin, John P. Leonard, Barbara Pro, Jennifer E. Amengual, Jia Ruan

Blood (2023) 142 (Supplement 1): 1698.

https://doi.org/10.1182/blood-2023-178231

Published: 2023

Journal Articles

Outcomes in Minorities with PTCL By Clinical Trial Enrollment

Seda S. Tolu, Alexander Sanjurjo, David Destephano, Barbara Pro, Jennifer E. Amengual

Blood (2023) 142 (Supplement 1): 4431.

https://doi.org/10.1182/blood-2023-177722

Published: 2023

Journal Articles

JAK1/2 Inhibition Modulates Key Markers of Lymphomagenesis in 9p24.1 Amplified Lymphoma, Priming for Enhanced Antigenicity

Seda S. Tolu, Ted B. Piorczynski, Manuel Pazos, II, Brian Estrella, Wenxuan Huang, Yun Kyoung Ryu, Hua-Jay J. Cherng, Barbara Pro, Jennifer E. Amengual

Blood (2023) 142 (Supplement 1): 6118.

https://doi.org/10.1182/blood-2023-180875

Published: 2023

Journal Articles

A Phase Ib Study to Evaluate the Safety and Efficacy of Nivolumab in Combination with R-CHOP in High-Risk DLBCL

Oluwatobi Odetola, Shuo Ma, Jane N. Winter, Barbara Pro, Ishan Roy, Ping Xie, Bin Zhang, George Koulogeorgas, Xinlei Mi, Robert Bayer, Robert Eisner, Valerie Nelson, Habib Shaikh, Dean Tsarwhas, Faisal Saghir, Parameswaran Venugopal, Leo I. Gordon, Reem Karmali

Blood (2023) 142 (Supplement 1): 4462.

https://doi.org/10.1182/blood-2023-185065

Published: 2023

Journal Articles

Methylated Whole Genome Cell-Free DNA Sequencing before Chimeric Antigen Receptor T-Cell Therapy for Large B-Cell Lymphoma Predicts Treatment Outcomes

Hua-Jay J. Cherng, Xiaojing Yang, Ryan Yancey, Christian A Gordillo, Ted B. Piorczynski, Hei T. Chan, Kenneth N. Ofori, Govind Bhagat, Andrea Califano, Barbara Pro, Keith Booher, Jennifer E. Amengual, Ran Reshef, Abu A. I. Sina

Blood (2023) 142 (Supplement 1): 4371.

https://doi.org/10.1182/blood-2023-178376

Published: 2023

Journal Articles

Phase II, Single Arm, Open Label, Single Center Study of Obinutuzumab and Ibrutinib in the Front Line Treatment of Indolent B-Cell Non-Hodgkin Lymphomas

Blood (2023) 142 (Supplement 1): 3028.

https://doi.org/10.1182/blood-2023-187847

Published: 2023

Journal Articles

How I treat posttransplant lymphoproliferative disorder

Jennifer E. Amengual, Barbara Pro

Blood (2023) 142 (17): 1426–1437.

https://doi.org/10.1182/blood.2023020075

Published: 2023

Journal Articles

The Effect of Rituximab Treatment and Reducing Immunosuppression on the Development of Post-Transplant Lymphoproliferative Disorder in EBV-Positive Patients after Solid Organ Transplantation

Evelyn Orlando, Maegan Ford, Zhezhen Jin, Andrew H. Lipsky, Ahmed Sawas, Barbara Pro, Jennifer E. Amengual

Blood (2022) 140 (Supplement 1): 12085–12086.

https://doi.org/10.1182/blood-2022-158050

Published: 2022

Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis

Eric D Jacobsen, Pier Luigi Zinzani, Jasmine Zain, Monica Mead, Carla Casulo, Giuseppe Gritti, Lauren C. Pinter-Brown, Koji Izutsu, Marci Daugherty, Jonathan E Brammer, Neha Mehta-Shah, Barbara Pro, Steven M. Horwitz

Blood (2022) 140 (Supplement 1): 9387–9389.

https://doi.org/10.1182/blood-2022-169432

Published: 2022

Journal Articles

Impact of Extranodal Disease Involvement on Outcomes in Post-Transplant Lymphoproliferative Disorder

Megan Melody, Frederique St. Pierre, Irene Helenowski, William B Pearse, Chetan V Vakkalagadda, Joseph R. Leventhal, John Friedewald, Bing Ho, Daniel Ganger, Jane N. Winter, Leo I. Gordon, Adam Yuh Lin, Reem Karmali, Shuo Ma, Barbara Pro, Jonathan Moreira

Blood (2022) 140 (Supplement 1): 6674–6675.

https://doi.org/10.1182/blood-2022-164724

Published: 2022

Journal Articles

Posttransplant Lymphoproliferative Disorder (PTLD) Following Transplantation at Northwestern University: Choice of Immunosuppressive Agents Does Not Impact Outcomes in PTLD

Megan Melody, Frederique St. Pierre, Irene Helenowski, William B Pearse, Chetan Vakkalagadda, Joseph R. Leventhal, Bing Ho, John Friedewald, Daniel Ganger, Jane N. Winter, Leo I. Gordon, Adam Yuh Lin, Reem Karmali, Shuo Ma, Barbara Pro, Jonathan Moreira

Blood (2022) 140 (Supplement 1): 3833–3834.

https://doi.org/10.1182/blood-2022-167812

Published: 2022

Journal Articles

Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy

Blood (2022) 140 (Supplement 1): 10955–10957.

https://doi.org/10.1182/blood-2022-160431

Published: 2022

NARROW

Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Final Results from the Phase 2 PRIMO Trial

Association between Food Insecurity, Financial Toxicity, and Healthcare Utilization in Patients with Lymphoma

Health Disparities in Lived Experiences of Patients with Cutaneous T-Cell Lymphoma: An All of Us Database Analysis

Combination JAK Inhibition and Immune Checkpoint Blockade for the Treatment of 9p Amplified Lymphomas

Extended Follow up and Immune Alterations in Patients with Classic Hodgkin Lymphoma (cHL) Treated with Frontline Single Agent Pembrolizumab Followed By AVD Chemotherapy

Diagnostic Utility of the 18 f-FDG PET/CT Scan in Solid Organ Transplant Patients with EBV Reactivation at Risk for Post-Transplant Lymphoproliferative Disorder

The Effect of Preemptive Rituximab Treatment in Patients with EBV Viremia after Solid Organ Transplantation on the Development of Post-Transplant Lymphoproliferative Disorder

Outcomes of Contemporary Novel Agent and Stem Cell Transplantation in Relapsed/Refractory PTCL

Outcomes in Minorities with PTCL By Clinical Trial Enrollment

JAK1/2 Inhibition Modulates Key Markers of Lymphomagenesis in 9p24.1 Amplified Lymphoma, Priming for Enhanced Antigenicity

A Phase Ib Study to Evaluate the Safety and Efficacy of Nivolumab in Combination with R-CHOP in High-Risk DLBCL

Methylated Whole Genome Cell-Free DNA Sequencing before Chimeric Antigen Receptor T-Cell Therapy for Large B-Cell Lymphoma Predicts Treatment Outcomes

Phase II, Single Arm, Open Label, Single Center Study of Obinutuzumab and Ibrutinib in the Front Line Treatment of Indolent B-Cell Non-Hodgkin Lymphomas

How I treat posttransplant lymphoproliferative disorder

The Effect of Rituximab Treatment and Reducing Immunosuppression on the Development of Post-Transplant Lymphoproliferative Disorder in EBV-Positive Patients after Solid Organ Transplantation

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis

Impact of Extranodal Disease Involvement on Outcomes in Post-Transplant Lymphoproliferative Disorder

Posttransplant Lymphoproliferative Disorder (PTLD) Following Transplantation at Northwestern University: Choice of Immunosuppressive Agents Does Not Impact Outcomes in PTLD

Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only